CLINICAL_TRIALS
trial_result
· 2006-05-18
Clinical Trial Update: Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant [Phase 2]
Summary
A Phase 2 study evaluating gemtuzumab ozogamicin in acute myeloid leukemia patients after stem cell transplant has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED